Inclusion Criteria:
- Pathologically confirmed high-risk recurrent/relapsed or refractory (R/R) classical
Hodgkin lymphoma (cHL), after non-response to or failure of first-line standard
therapy prior to a definitive therapy e.g.high-dose chemotherapy/autologous stem cell
transplant (HDCT/ASCT)
- Participants with pathologically confirmed R/R NHL after failure or non-response to
second line therapy, including but not limited to primary mediastinal B-cell lymphoma,
diffuse large B-cell lymphoma (DLBCL), mediastinal gray zone lymphoma (MGZL),
anaplastic large cell lymphoma (ALCL), or peripheral T-cell lymphoma (PTCL).
- Participants must have measurable PET positive disease in both cHL and NHL cohorts.
Exclusion Criteria:
- Aggressive B-cell lymphomas subtypes including Burkitt lymphoma (BL), lymphoblastic
lymphoma, and NK/T-cell lymphoma/leukemia.
- Primary CNS lymphoma of the brain or spinal cord, and secondary CNS lymphoma (ie, from
systemic non-Hodgkin lymphoma) involving the brain, spinal cord, or with
leptomeningeal seeding.
- Prior treatment with an anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA-4)
antibody, or any other antibody or drug specifically targeting T-cell co-stimulation
or checkpoint pathways, with the exception of anti-PD(L)-1 targeted therapies
- Prior treatment with lymphocyte activation gene-3 (LAG-3)-targeted agents
- Prior autologous stem cell transplantation (HDCT/ASCT)
- History of allogeneic bone marrow transplantation.
Other protocol-defined inclusion/exclusion criteria apply
Recruiting
